SS Innovations International, Inc. (NASDAQ: SSII) has taken a critical step toward bringing its SSi Mantra surgical robotic system to the United States. The company announced on October 5, 2026, that it submitted its response to the U.S. Food and Drug Administration's (FDA) request for additional information regarding its 510(k) submission for the SSi Mantra. The response includes final data from an expanded human clinical and human factors validation study, along with a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal.
The company anticipates that the FDA will complete its review of the response and the 510(k) submission in the first quarter of 2027. If cleared, the SSi Mantra would enter the U.S. market, where it could disrupt the surgical robotics landscape by offering a more affordable and accessible alternative to existing systems. This matters because surgical robotics has long been dominated by high-cost players, limiting adoption to well-funded hospitals. SS Innovations aims to change that dynamic, with a vision to make robotic surgery affordable and accessible to a larger segment of the global population.
The SSi Mantra is a modular, multi-arm system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient-related information. It also includes a virtual real-time image of the robotic patient-side arm carts and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console provides a portable, compact alternative to the standard command center, enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to improve safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures.
For investors, the FDA submission represents a key milestone that could unlock significant value. The U.S. surgical robotics market is substantial, and a lower-cost, clinically validated system could capture share from established competitors. SS Innovations, headquartered in India but a U.S. company, is focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. The company's progress is closely tracked by investors and industry observers, with updates available in its newsroom at https://ibn.fm/SSII. The full press release can be viewed at https://ibn.fm/A6dJ8. For more information about the company, visit ssinnovations.com or its LinkedIn page.
The news was distributed through TechMediaWire, a specialized communications platform focused on pioneering companies driving the future of technology. TechMediaWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
